101 results on '"Tischler V"'
Search Results
2. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
- Author
-
Finn, S.P. Addeo, A. Dafni, U. Thunnissen, E. Bubendorf, L. Madsen, L.B. Biernat, W. Verbeken, E. Hernandez-Losa, J. Marchetti, A. Cheney, R. Warth, A. Speel, E.-J.M. Quinn, A.M. Monkhorst, K. Jantus-Lewintre, E. Tischler, V. Marti, N. Dimopoulou, G. Molina-Vila, M.A. Kammler, R. Kerr, K.M. Peters, S. Stahel, R.A. European Thoracic Oncology Platform Lungscape Investigators
- Abstract
Introduction: KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). Methods: KRAS mutations were evaluated in formalin-fixed, paraffin-embedded tissue sections by a microfluidic-based multiplex polymerase chain reaction platform as a component of the previously published European Thoracic Oncology Platform Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I to III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathologic characteristics, molecular profiles, and postoperative patient outcome (overall survival, relapse-free survival, time-to-relapse) were explored. Results: KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 [49%]) with I or II or III stage respective distribution of 53% or 24% or 22% and median follow-up of 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0% (95% confidence interval (CI): 35.0% to 41.0%), with Kr_G12C mutation representing 17.0% (95% CI: 14.7% to 19.4%). In the “histologic-subtype” cohort, Kr_G12C prevalence was 10.5% (95% CI: 9.2% to 11.9%). When adjusting for clinicopathologic characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or nonexistence of KRAS mutation was identified in the adenocarcinoma cohort alone and in the “histologic-subtype” cohort. For overall survival in adenocarcinomas, hazard ratio (HR)G12C versus other KRAS is equal to 1.39 (95% CI: 1.03 to 1.89, p = 0.031) and HRG12C versus no KRAS is equal to 1.32 (95% CI: 1.03 to 1.69, p = 0.028) (both also significant in the “histologic-subtype” cohort). For time-to-relapse, HRG12C versus other KRAS is equal to 1.41 (95% CI: 1.03 to 1.92, p = 0.030). In addition, among all patients, for relapse-free survival, HRG12C versus no KRAS is equal to 1.27 (95% CI: 1.04 to 1.54, p = 0.017). Conclusions: In this large, clinically annotated stage I to III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathologic characteristics) among adenocarcinomas and in unselected NSCLCs. © 2021 International Association for the Study of Lung Cancer
- Published
- 2021
3. Evaluation of a mental health outreach service for homeless families. (Original Article)
- Author
-
Tischler, V., Vostanis, P., Bellerby, T., and Cumella, S.
- Subjects
Community psychiatric services -- Evaluation -- Services ,Homeless children -- Services ,Family and marriage ,Health ,Evaluation ,Services - Abstract
Aims: To describe the characteristics of homeless children and families seen by the mental health outreach service [MHOS], to evaluate the impact of this service on the short term psychosocial [...]
- Published
- 2002
4. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project
- Author
-
Kerr, K.M. Dafni, U. Schulze, K. Thunnissen, E. Bubendorf, L. Hager, H. Finn, S. Biernat, W. Vliegen, L. Losa, J.H. Marchetti, A. Cheney, R. Warth, A. Speel, E.-J. Blackhall, F. Monkhorst, K. Jantus Lewintre, E. Tischler, V. Clark, C. Bertran-Alamillo, J. Meldgaard, P. Gately, K. Wrona, A. Vandenberghe, P. Felip, E. De Luca, G. Savic, S. Muley, T. Smit, E.F. Dingemans, A.-M.C. Priest, L. Baas, P. Camps, C. Weder, W. Polydoropoulou, V. Geiger, T.R. Kammler, R. Sumiyoshi, T. Molina, M.A. Shames, D.S. Stahel, R.A. Peters, S. Boss, V. ETOP Lungscape Consortium
- Abstract
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods: Clinically annotated, resected stage I-III NSCLC FFPE tissue was assessed for gene mutation using a microfluidicsbased multiplex PCR platform. Mutant-allele detection sensitivity is>1% for most of the 150 (13 genes) mutations covered in the multiplex test. Results: Multiplex testing has been carried out in 2063 (76.2%) of the 2709 Lungscape cases (median follow-up 4.8 years). FFPE samples mostly date from 2005 to 2008, yet recently extracted DNA quality and quantity was generally good. Average DNA yield/case was 2.63 mg; 38 cases (1.4%) failed QC and were excluded from study; 95.1% of included cases allowed the complete panel of mutations to be tested. Most common were KRAS, MET, EGFR and PIK3CA mutations with overall prevalence of 23.0%, 6.8%, 5.4% and 4.9%, respectively. KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas. MET mutation prevalence did not differ between histology groups. EGFR mutations were found predominantly in never smokers; KRAS in current/former smokers. For all the above mutations, there was no difference in outcome between mutated and non-mutated cases. Conclusion: Archival FFPE NSCLC material is adequate for multiplex mutation analysis. In this large, predominantly European, clinically annotated stage I-III NSCLC cohort, none of the mutations characterized showed prognostic significance. © The Author 2017.
- Published
- 2018
5. Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma
- Author
-
Tischler, V., Ihle, M. A., Stenzinger, A., Weichert, W., Jochum, W., Buettner, R., Wolf, J., Peifer, M., Thomas, R., Tischler, V., Ihle, M. A., Stenzinger, A., Weichert, W., Jochum, W., Buettner, R., Wolf, J., Peifer, M., and Thomas, R.
- Published
- 2018
6. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
- Author
-
George, J, Walter, V, Peifer, M, Alexandrov, LB, Seidel, D, Leenders, F, Maas, L, Mueller, C, Dahmen, I, Delhomme, TM, Ardin, M, Leblay, N, Byrnes, G, Sun, R, De Reynies, A, McLeer-Florin, A, Bosco, G, Malchers, F, Menon, R, Altmuller, J, Becker, C, Nurnberg, P, Achter, V, Lang, U, Schneider, PM, Bogus, M, Soloway, MG, Wilkerson, MD, Cun, Y, McKay, JD, Moro-Sibilot, D, Brambilla, CG, Lantuejoul, S, Lemaitre, N, Soltermann, A, Weder, W, Tischler, V, Brustugun, OT, Lund-Iversen, M, Helland, A, Solberg, S, Ansen, S, Wright, G, Solomon, B, Roz, L, Pastorino, U, Petersen, I, Clement, JH, Saenger, J, Wolf, J, Vingron, M, Zander, T, Perner, S, Travis, WD, Haas, SA, Olivier, M, Foll, M, Buettner, R, Hayes, DN, Brambilla, E, Fernandez-Cuesta, L, Thomas, RK, George, J, Walter, V, Peifer, M, Alexandrov, LB, Seidel, D, Leenders, F, Maas, L, Mueller, C, Dahmen, I, Delhomme, TM, Ardin, M, Leblay, N, Byrnes, G, Sun, R, De Reynies, A, McLeer-Florin, A, Bosco, G, Malchers, F, Menon, R, Altmuller, J, Becker, C, Nurnberg, P, Achter, V, Lang, U, Schneider, PM, Bogus, M, Soloway, MG, Wilkerson, MD, Cun, Y, McKay, JD, Moro-Sibilot, D, Brambilla, CG, Lantuejoul, S, Lemaitre, N, Soltermann, A, Weder, W, Tischler, V, Brustugun, OT, Lund-Iversen, M, Helland, A, Solberg, S, Ansen, S, Wright, G, Solomon, B, Roz, L, Pastorino, U, Petersen, I, Clement, JH, Saenger, J, Wolf, J, Vingron, M, Zander, T, Perner, S, Travis, WD, Haas, SA, Olivier, M, Foll, M, Buettner, R, Hayes, DN, Brambilla, E, Fernandez-Cuesta, L, and Thomas, RK
- Abstract
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung cancers, but their precise relationship has remained unclear. Here we perform a comprehensive genomic (n = 60) and transcriptomic (n = 69) analysis of 75 LCNECs and identify two molecular subgroups: "type I LCNECs" with bi-allelic TP53 and STK11/KEAP1 alterations (37%), and "type II LCNECs" enriched for bi-allelic inactivation of TP53 and RB1 (42%). Despite sharing genomic alterations with adenocarcinomas and squamous cell carcinomas, no transcriptional relationship was found; instead LCNECs form distinct transcriptional subgroups with closest similarity to SCLC. While type I LCNECs and SCLCs exhibit a neuroendocrine profile with ASCL1high/DLL3high/NOTCHlow, type II LCNECs bear TP53 and RB1 alterations and differ from most SCLC tumors with reduced neuroendocrine markers, a pattern of ASCL1low/DLL3low/NOTCHhigh, and an upregulation of immune-related pathways. In conclusion, LCNECs comprise two molecularly defined subgroups, and distinguishing them from SCLC may allow stratified targeted treatment of high-grade neuroendocrine lung tumors.
- Published
- 2018
7. 155OCHEMOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA DOES NOT PRECLUDE USE OF CHECK-POINT BLOCKADE
- Author
-
Curioni Fontecedro, A., Cecconi, V., Felley Bosco, E., Schmitt-Opitz, I., Weder, W., Stahel, R.A., van den Broek, M., and Tischler, V.
- Published
- 2017
8. Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer
- Author
-
Plenker, D., Riedel, M., Brägelmann, J., Dammert, M. A., Chauhan, R., Knowles, P. P., Lorenz, C., Keul, M., Bührmann, M., Pagel, O., Tischler, V., Scheel, A. H., Schütte, D., Song, Y., Stark, J., Mrugalla, F., Alber, Y., Richters, A., Engel, J., Leenders, F., Heuckmann, J. M., Wolf, J., Diebold, J., Pall, G., Peifer, M., Aerts, M., Gevaert, K., Zahedi, R. P., Buettner, R., Shokat, K. M., McDonald, N. Q., Kast, S. M., Gautschi, O., Thomas, R. K., and Sos, M. L.
- Subjects
Gene Rearrangement ,congenital, hereditary, and neonatal diseases and abnormalities ,endocrine system ,Lung Neoplasms ,endocrine system diseases ,Proto-Oncogene Proteins c-ret ,Imidazoles ,Adenocarcinoma of Lung ,Adenocarcinoma ,bcs ,Heterocyclic Compounds, 4 or More Rings ,Article ,Pyridazines ,Cytoskeletal Proteins ,Mice ,Drug Resistance, Neoplasm ,Cell Line, Tumor ,Mutation ,NIH 3T3 Cells ,Animals ,Humans ,Protein Kinase Inhibitors - Abstract
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. Here, we provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors such as AD80 or ponatinib that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in RET-rearranged cells we identify the CCDC6-RETI788N mutation and drug-induced MAPK pathway reactivation as possible mechanisms, by which tumors may escape the activity of RET inhibitors. Our data provide mechanistic insight into the druggability of RET kinase fusions that may be of help for the development of effective therapies targeting such tumors.
- Published
- 2017
9. 22P Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma
- Author
-
Tischler, V., primary, Ihle, M.A., additional, Stenzinger, A., additional, Weichert, W., additional, Jochum, W., additional, Büttner, R., additional, Wolf, J., additional, Peifer, M., additional, and Thomas, R., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Dementia and Imagination: A mixed-methods protocol for arts and science research
- Author
-
Windle, G, Newman, A, Burholt, V, Woods, B, O'Brien, D, Baber, M, Hounsome, B, Parkinson, C, Tischler, V, Windle, G, Newman, A, Burholt, V, Woods, B, O'Brien, D, Baber, M, Hounsome, B, Parkinson, C, and Tischler, V
- Abstract
Introduction: Dementia and Imagination is a multidisciplinary research collaboration bringing together arts and science to address current evidence limitations around the benefits of visual art activities in dementia care. The research questions ask: Can art improve quality of life and well-being? If it does make a difference, how does it do this - and why? Does it have wider social and community benefits? Methods and analysis: This mixed-methods study recruits participants from residential care homes, National Health Service (NHS) wards and communities in England and Wales. A visual art intervention is developed and delivered as 1×2-hour weekly group session for 3 months in care and community settings to N=100 people living with dementia. Quantitative and qualitative data are collected at 3 time points to examine the impact on their quality of life, and the perceptions of those who care for them (N=100 family and professional carers). Repeated-measures systematic observations of well-being are obtained during the intervention (intervention vs control condition). The health economics component conducts a social return on investment evaluation of the intervention. Qualitative data are collected at 3 time points (n=35 carers/staff and n=35 people living with dementia) to explore changes in social connectedness. Self-reported outcomes of the intervention delivery are obtained (n=100). Focus groups with intervention participants (n=40) explore perceptions of impact. Social network analysis of quantitative and qualitative data from arts and healthcare professionals (N=100) examines changes in perceptions and practice. Ethics and dissemination: The study is approved by North Wales Research Ethics Committee - West. A range of activities will share the research findings, including international and national academic conferences, quarterly newsletters and the project website. Public engagement projects will target a broad range of stakeholders. Policy and practice summaries
- Published
- 2016
11. Carrying out research across the arts and humanities and social sciences: developing the methodology for Dementia and Imagination
- Author
-
Newman, A, Baber, M, O Brien, D, Goulding, A, Jones, CH, Howson, T, Jones, C, Parkinson, C, Taylor, K, Tischler, V, Windle, G, Newman, A, Baber, M, O Brien, D, Goulding, A, Jones, CH, Howson, T, Jones, C, Parkinson, C, Taylor, K, Tischler, V, and Windle, G
- Abstract
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This paper analyses how the methodological approach for a major Arts and Humanities Research Council and Economic and Social Research Council-funded project entitled Dementia and Imagination1 was formulated. This multidisciplinary project brings together the arts and humanities with the social sciences with their different epistemological philosophies and subsequent understandings of research methods. The main objective was to determine how visual arts activities may change, sustain and catalyse community cultures, beliefs, attitudes and behaviours to create dementia-friendly communities. This project involves 6 different UK universities, 14 researchers, 10 formal partners, 7 project artists, 3 research artists and a large number of civil society organisations. The analysis presents a series of themes that have been identified as influencing the approach taken to develop methods which aimed to speak to different audiences in the social sciences, arts and humanities, policy/practice and public domains. It is concluded that a research project of this type needs to embrace a wide variety of epistemological positions if it is to successfully achieve its objectives. This paper contributes to knowledge about how the methodology of large-scale multidisciplinary projects may be constructed which will be of value to those building research consortia across different universities and between universities and community partners.
- Published
- 2016
12. Frequent PD-L1 expression in testicular germ cell tumors
- Author
-
Fankhauser, C D, Curioni-Fontecedro, A, Allmann, V, Beyer, J, Tischler, V, Sulser, T, Moch, H, Bode, P K, Fankhauser, C D, Curioni-Fontecedro, A, Allmann, V, Beyer, J, Tischler, V, Sulser, T, Moch, H, and Bode, P K
- Abstract
BACKGROUND Many testicular germ cell cancers are curable despite metastatic disease, but about 10-15% of patients fail cisplatin-based first-line treatment. Immunotherapy is considered as additional treatment approach for these patients. Inhibition of the interaction between Programmed Death Receptor 1 (PD-1) and Programmed Death Receptor Ligand 1 (PD-L1) enhances T-cell responses in vitro and mediates clinical antitumour activity. We analysed the expression of PD-L1 in testicular germ cell tumours to evaluate its potential as target for immunotherapeutic strategies. METHODS Immunohistochemistry was performed in 479 formalin-fixed paraffin-embedded specimens using a rabbit monoclonal antibody (E1L3N). The tissue microarray consisted of 208 pure seminomas, 121 non-seminomas, 20 intratubular germ cell neoplasia unclassified (IGCNU) and 20 specimens of non-neoplastic testicular tissue. RESULTS Programmed Death Receptor Ligand-1 expression was found in 73% of all seminomas and in 64% of all non-seminomas. None of 20 IGCNU and none of 20 normal tissue specimens exhibited PD-L1 expression. PD-L1 positive stromal cells were only detected in seminomas, but not in non-seminomas. The anti PD-L1 antibody showed a pre-dominantly membranous staining pattern in testicular tumour cells, as well as expression in stromal cells. CONCLUSIONS This frequent expression of PD-L1 in human testicular germ cell tumours suggests that patients with testicular germ cell tumours could profit from immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies.
- Published
- 2015
13. Frequent PD-L1 expression in testicular germ cell tumors
- Author
-
Fankhauser, C D, primary, Curioni-Fontecedro, A, additional, Allmann, V, additional, Beyer, J, additional, Tischler, V, additional, Sulser, T, additional, Moch, H, additional, and Bode, P K, additional
- Published
- 2015
- Full Text
- View/download PDF
14. Chemotherapy of Malignant Pleural Mesothelioma Does not Preclude Use of Check-Point Blockade
- Author
-
Curioni Fontecedro, A., primary, Cecconi, V., additional, Felley Bosco, E., additional, Schmitt-Opitz, I., additional, Weder, W., additional, Stahel, R.A., additional, van den Broek, M., additional, and Tischler, V., additional
- Published
- 2015
- Full Text
- View/download PDF
15. EGFR-Status beim Lungen-Adeno-Ca
- Author
-
Soltermann, A, Tischler, V, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2009
16. Prevalence and Clinical Outcomes for Patients with Met Protein Expression in Patients with Non-Small Cell Lung Cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project
- Author
-
Bubendorf, L., primary, Dafni, O., additional, Tischler, V., additional, Finn, S., additional, Biernat, W., additional, Verbeken, E., additional, Hager, H., additional, Murtra, N., additional, Thunnissen, E., additional, Nonaka, D., additional, Warth, A., additional, Speel, E.J., additional, Savic, S., additional, Martorell, M., additional, Tsourti, Z., additional, Schulze, K., additional, Das-Gupta, A., additional, Kerr, K.M., additional, Peters, S., additional, and Stahel, R.A., additional
- Published
- 2014
- Full Text
- View/download PDF
17. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer
- Author
-
Collaud, S, Lardinois, D, Tischler, V, Steinert, H C, Stahel, R, Weder, W, Collaud, S, Lardinois, D, Tischler, V, Steinert, H C, Stahel, R, and Weder, W
- Abstract
OBJECTIVES: Restaging of patients with locally advanced non-small-cell lung cancer (NSCLC) is of paramount importance, since only patients with down-staging after induction therapy will benefit from surgery. In this study, we assessed the aetiology of new (18)fluoro-2-deoxy-d-glucose (FDG)-positive focal abnormalities on restaging positron emission tomography/computed tomography (PET/CT) in patients with a good response after induction chemotherapy in the primary tumour and lymph nodes. METHODS: Between 2004 and 2008, 31 patients with histological proven stage III NSCLC had a PET/CT prior and after induction chemotherapy. Their medical charts were retrospectively reviewed. RESULTS: Restaging PET/CT revealed a new FDG-positive lesion in 6 of 31 (20%) patients. The initial clinical stage of the disease was IIIA N2 in four and IIIB T4 in two patients. The maximal standard uptake value in the primary tumour (P = 0.043) and in the initially involved mediastinal nodes (P = 0.068) decreased after induction treatment in all patients. The new PET/CT findings were located in an ipsilateral cervical lymph node in two patients, a contralateral mediastinal in one patient and an ipsilateral mammary internal lymph node in one patient. Two other patients had a lesion on the contralateral lung. Malignant lymph node infiltrations were excluded following fine-needle puncture, intraoperative biopsy or follow-up PET/CT. Contralateral pulmonary lesions were diagnosed as benign following mini thoracotomy and pulmonary wedge resection.CONCLUSIONS: New solitary FDG-positive lesions on restaging PET/CT after induction chemotherapy for NSCLC are not rare in good responders to chemotherapy. In our experience, all these lesions were not associated with malignancy.
- Published
- 2012
18. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer
- Author
-
Tischler, V, Pfeifer, M, Hausladen, S, Schirmer, U, Bonde, A K, Kristiansen, G, Sos, M L, Weder, W, Moch, H, Altevogt, P, Soltermann, A, Tischler, V, Pfeifer, M, Hausladen, S, Schirmer, U, Bonde, A K, Kristiansen, G, Sos, M L, Weder, W, Moch, H, Altevogt, P, and Soltermann, A
- Abstract
Background: The L1 cell adhesion molecule (L1CAM) is potentially involved in epithelial-mesenchymal transition (EMT). EMT marker expression is of prognostic significance in non-small cell lung cancer (NSCLC). The relevance of L1CAM for NSCLC is unclear. We investigated the protein expression of L1CAM in a cohort of NSCLC patients. L1CAM protein expression was correlated with clinico-pathological parameters including survival and markers of epithelial-mesenchymal transition. Results: L1CAM protein expression was found in 25% of squamous cell carcinomas and 24% of adenocarcinomas and correlated with blood vessel invasion and metastasis (p < 0.05). L1CAM was an independent predictor of survival in a multivariate analysis including pT, pN, and pM category, and tumor differentiation grade. L1CAM expression positively correlated with vimentin, beta-catenin, and slug, but inversely with E-cadherin (all p-values < 0.05). E-cadherin expression was higher in the tumor center than in the tumor periphery, whereas L1CAM and vimentin were expressed at the tumor-stroma interface. In L1CAM-negative A549 cells the L1CAM expression was upregulated and matrigel invasion was increased after stimulation with TGF-beta1. In L1CAM-positive SK-LU-1 and SK-LC-LL cells matrigel invasion was decreased after L1CAM siRNA knockdown. Conclusions: A subset of NSCLCs with vessel tropism and increased metastasis aberrantly expresses L1CAM. L1CAM is a novel prognostic marker for NSCLCs that is upregulated by EMT induction and appears to be instrumental for enhanced cell invasion.
- Published
- 2011
19. Periostin is up-regulated in high grade and high stage prostate cancer
- Author
-
Tischler, V, Fritzsche, F R, Wild, P J, Stephan, C, Seifert, H H, Riener, M O, Hermanns, T, Mortezavi, A, Gerhardt, J, Schraml, P, Jung, K, Moch, H, Soltermann, A, Kristiansen, G, Tischler, V, Fritzsche, F R, Wild, P J, Stephan, C, Seifert, H H, Riener, M O, Hermanns, T, Mortezavi, A, Gerhardt, J, Schraml, P, Jung, K, Moch, H, Soltermann, A, and Kristiansen, G
- Abstract
BACKGROUND: Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far. METHODS: Here, we evaluated periostin expression in prostate cancer cells and peritumoural stroma immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n = 93) and a test cohort (n = 325). Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed. RESULTS: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%). Increased periostin expression in carcinoma cells was significantly associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort. Whereas periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in tumour stroma was found in most primary and metastatic prostate cancers. High stromal periostin expression was associated with higher Gleason scores (p < 0.001). There was a relationship between stromal periostin expression and shortened PSA relapse free survival times in the training cohort (p < 0.05). CONCLUSIONS: Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.
- Published
- 2010
20. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival No conflicts of interest were declared.
- Author
-
Department of Pathology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA, Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA ; SP and PW contributed equally to this study and should both be considered first authors., Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA, Institute of Surgical Pathology, Department of Pathology, University Hospital of Zurich, Zurich, Switzerland, Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA ; Broad Institute of Harvard and M.I.T, Cambridge, MA, USA, Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland, Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA ; Broad Institute of Harvard and M.I.T, Cambridge, MA, USA ; Department of Pathology, Harvard Medical School, Boston, MA, USA, Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA ; Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA., Perner, S., Wagner, P. L., Soltermann, A., LaFargue, C., Tischler, V., Weir, B. A., Weder, W., Meyerson, M., Giordano, T. J., Moch, H., Rubin, M. A., Department of Pathology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA, Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA ; SP and PW contributed equally to this study and should both be considered first authors., Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA, Institute of Surgical Pathology, Department of Pathology, University Hospital of Zurich, Zurich, Switzerland, Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA ; Broad Institute of Harvard and M.I.T, Cambridge, MA, USA, Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland, Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA ; Broad Institute of Harvard and M.I.T, Cambridge, MA, USA ; Department of Pathology, Harvard Medical School, Boston, MA, USA, Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA ; Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA., Perner, S., Wagner, P. L., Soltermann, A., LaFargue, C., Tischler, V., Weir, B. A., Weder, W., Meyerson, M., Giordano, T. J., Moch, H., and Rubin, M. A.
- Abstract
Acquired chromosomal aberrations play an important role in tumour development and progression. Such genetic alterations occur in a significant proportion of non-small cell lung carcinomas (NSCLCs) and include amplification of 14q13.3, which contains the TTF1 gene. We asked whether TTF1 amplification is associated with increased TTF1 protein expression in NSCLCs, and whether TTF1 is associated with clinicopathological features, including patient survival. We used a FISH assay and quantitative immunohistochemical staining to interrogate a population-based cohort of 538 NSCLCs from Swiss patients for TTF1 amplification and protein expression. We found TTF1 amplification in ???13% of adenocarcinomas (ACs) and in ???9% of squamous cell carcinomas (SCCs) and TTF1 amplification was associated with increased TTF1 protein expression. High-level TTF1 expression was significantly associated with smaller tumour size, female gender and longer overall survival only among ACs (median survival 82 versus 28 months; p = 0.002). On multivariate analysis, high TTF1 expression was an independent predictor of favourable prognosis in patients with AC [hazard ratio, 0.56 (95% CI 0.38???0.83); p = 0.008]. We conclude that TTF1 amplification is a mechanism of high-level TTF1 expression in a subset of NSCLCs. When expressed at high levels, this routinely used diagnostic marker is also an independent biomarker of favourable prognosis in AC. Copyright ?? 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Published
- 2009
21. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer
- Author
-
Collaud, S., primary, Lardinois, D., additional, Tischler, V., additional, Steinert, H. C., additional, Stahel, R., additional, and Weder, W., additional
- Published
- 2011
- Full Text
- View/download PDF
22. A Unique Design for a Diverging Flexible Vertical Tail
- Author
-
DAIMLER CHRYSLER AEROSPACE MUNICH (GERMANY) MILITARY AIRCRAFT, Sensburg, O., Schneider, G., Tischler, V., Venkayya, V., DAIMLER CHRYSLER AEROSPACE MUNICH (GERMANY) MILITARY AIRCRAFT, Sensburg, O., Schneider, G., Tischler, V., and Venkayya, V.
- Abstract
A method is developed which allows to use the flexible behaviour of aircraft structures to enhance aerodynamic derivatives. A vertical tail analytical model was used to show these effects and by exploiting the aeroelastic deflections it is possible to reduce the area of this sunface up to thirty percent. Numerous applications are possible including fighter and transport airplanes. Since composite structues are involved it is absolutely necessary to use a multidisciplinary optimisation program code such as the US-Airforce ASTROS-code., Presented at the Specialists' Meeting of the RTO Applied Vehicle Technology Panel (AVT) held in Ottawa, Canada, 18-20 Oct 1999. This article is from ADA388195 Structural Aspects of Flexible Aircraft Control (les Aspects structuraux du controle actif et flexible des aeronefs)
- Published
- 2000
23. Multidisciplinary Design Optimization of a Built-Up Wing Structure with Tip Missile
- Author
-
Jun, Seungmoon, primary, Tischler, V. A., additional, and Venkayya, V. B., additional
- Published
- 2003
- Full Text
- View/download PDF
24. 1199PD - Prevalence and Clinical Outcomes for Patients with Met Protein Expression in Patients with Non-Small Cell Lung Cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project
- Author
-
Bubendorf, L., Dafni, O., Tischler, V., Finn, S., Biernat, W., Verbeken, E., Hager, H., Murtra, N., Thunnissen, E., Nonaka, D., Warth, A., Speel, E.J., Savic, S., Martorell, M., Tsourti, Z., Schulze, K., Das-Gupta, A., Kerr, K.M., Peters, S., and Stahel, R.A.
- Published
- 2014
- Full Text
- View/download PDF
25. Flutter Prediction Methods for Aeroelastic Design Optimization
- Author
-
Pidaparti, R. M. V., primary, Tischler, V. A., additional, and Venkayya, V. B., additional
- Published
- 2001
- Full Text
- View/download PDF
26. Aeroelastic Tailoring of Composite Structures
- Author
-
Eastep, F. E., primary, Tischler, V. A., additional, Venkayya, V. B., additional, and Khot, N. S., additional
- Published
- 1999
- Full Text
- View/download PDF
27. Design Optimization of Airframe Structures
- Author
-
Tischler, V. A., primary, Venkayya, V. B., additional, and Bharatram, G., additional
- Published
- 1997
- Full Text
- View/download PDF
28. Multidisciplinary Design Optimization of a Built-Up Wing Structure with Tip Missile.
- Author
-
Seungmoon Jun, Eli, Tischler, V. A., and Venkayya, V. B.
- Subjects
- *
AIRPLANE wings , *AEROELASTICITY , *AIRFRAMES , *WINGS (Anatomy) , *AERODYNAMICS - Abstract
The influence of a wing tip missile on the design optimization of a wing structure is studied. Finite element models of a realistic built-up wing structure are used to represent stiffness and mass properties. The store location and the effect of the store aerodynamics and mass are the variables included. A multidisciplinary optimization technique is used to compensate/restore the lost aeroelastic performance due to the presence of the store. Missile locations are the only configuration variables addressed besides the structural variables. The built-up wing box structure is optimized with constraints on the static strength and flutter speed. The thickness and the cross-sectional areas of the structural elements are the primary variables in the optimization. The aerodynamics of the tip missile has a significant effect on the flutter characteristics. In addition, the flutter behavior of the optimized structure is very sensitive to the tip missile movement along the tip chord. The results indicate that the effect of the tip missile aft movement must be examined in conjunction with the store aerodynamics. ASTROS is the primary tool used. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
29. Recent Studies on Bolted Joints in Composite Structures
- Author
-
AIR FORCE WRIGHT AERONAUTICAL LABS WRIGHT-PATTERSON AFB OH, Venkayya, V. B., Ramkumar, R. L., Tischler, V. A., Snyder, B. D., Burns, J. G., AIR FORCE WRIGHT AERONAUTICAL LABS WRIGHT-PATTERSON AFB OH, Venkayya, V. B., Ramkumar, R. L., Tischler, V. A., Snyder, B. D., and Burns, J. G.
- Abstract
A brief review of recent Air Force programs in bolted joints in composite structures was presented in this paper. The review included analytical methods development and experimental verification. Analytical methods addressed both single fastener and multifastener joints. A number of joint design variables, such as, finite geometry, fastener arrangement, joint service environment, and a number of relevant parameters were addressed in these programs. The test programs included static and fatigue specimens. Single fastener and multifastener joint tests were conducted to correlate the analysis results. Full scale test specimens were used to verify the overall analysis strategy. A comprehensive design guide was developed for the design and analysis of bolted joints in composite structures. This design guide is supported by four computer programs. (SDW), This article is from 'Behaviour and Analysis of Mechanically Fastened Joints in Composite Structures', AD-A199 171, p3-1 - 3-14.
- Published
- 1988
30. A Computer Program for Counting Load Spectrum Cycles Based on the Range Pair Cycle Counting Method
- Author
-
AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OH, Tischler, V. A., AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OH, and Tischler, V. A.
- Abstract
This report presents a detailed description of a computer program based on the Range Pair Cycle Counting Method. The Range Pair Cycle Counting Method is a procedure for generating an analysis spectrum from a given load spectrum. Examples are presented where the resulting analysis spectrum will be used as input to a crack growth analysis program.
- Published
- 1972
31. Application of Optimality Criterion to Fiber-Reinforced Composites.
- Author
-
AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OHIO, Khot,N. S., Venkayya,V. B., Johnson,C. D., Tischler,V. A., AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OHIO, Khot,N. S., Venkayya,V. B., Johnson,C. D., and Tischler,V. A.
- Abstract
AYYA,V. B. ;Johnson,C. D. ;Tischler,V. A. ;AFFDL-TR-73-6(*composite materials, optimization), (*airframes, composite materials), aluminum, boron, epoxy resins, fibers, alignment, wings, panels, weight, numerical analysis, laminatesfinite element analysis, *fiber compositesThis report presents an efficient optimization method, based on an optimality criterion and a numerical search, for the minimum weight design of structures made from boron/epoxy composite materials. A RECURRENCE RELATION IS DERIVED AND IS INCORPORATED INTO THE COMPUTER PROGRAM BASED ON THE DISPLACEMENT METHOD OF FINITE ELEMENT ANALYSIS. The optimum design procedure takes into consideration multiple loading conditions and displacement constraints on the structure. Several sample problems consisting of both isotropic and composite elements are solved and the results are presented. (Author, modified-PL)
- Published
- 1973
32. COMPUTER GRAPHICS TECHNIQUES FOR STRUCTURAL SHELL ANALYSIS.
- Author
-
AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OHIO, Purdy,D. M., Bernstein,T. N., Tischler,V. A., AIR FORCE FLIGHT DYNAMICS LAB WRIGHT-PATTERSON AFB OHIO, Purdy,D. M., Bernstein,T. N., and Tischler,V. A.
- Abstract
Complex shell of revolution problems are frequently encountered in the design of aerospace vehicles. Several techniques have evolved which will provide satisfactory solutions for these problems. The three techniques which have become the most widely used, namely the discrete element approach, the finite difference approach, and direct numerical integration, all require the use of a digital computer. In the present paper, a method is developed which will transform the solutions, regardless of how they are obtained, into functions of a single, consistent, independent variable. This transformation which is straightforward for shells such as cylinders, cones, and spheres but complex for shells such as paraboloids, ellipsoids, and hyperboloids, makes it possible to obtain a consistent graphical representative of the variables over the entire shell. This method is applied to an existing shell analysis program and solutions to selected problems are obtained in graphical form. The computer routines required for the plotting of solutions and the instructions for modification of existing shell analysis computer programs are included. (Author)
- Published
- 1969
33. 155OCHEMOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA DOES NOT PRECLUDE USE OF CHECK-POINT BLOCKADE
- Author
-
Curioni Fontecedro, A., Cecconi, V., Felley Bosco, E., Schmitt-Opitz, I., Weder, W., Stahel, R.A., van den Broek, M., Tischler, V., Curioni Fontecedro, A., Cecconi, V., Felley Bosco, E., Schmitt-Opitz, I., Weder, W., Stahel, R.A., van den Broek, M., and Tischler, V.
34. The relation between the renal excretion of inorganic phosphate and sodium during chronic ammonium chloride load in infants
- Author
-
Mathéová, E, primary, Pavkovčeková, O, additional, Tischler, V, additional, and Beňo, P, additional
- Published
- 1974
- Full Text
- View/download PDF
35. Renal excretion of calcium in infants during chronic acid and bicarbonate load
- Author
-
Démant, F, primary, Pavkovčeková, O, additional, Mátheová, E, additional, Tischler, V, additional, and Beňo, P, additional
- Published
- 1974
- Full Text
- View/download PDF
36. THE RENAL RESPONSE TO CHRONIC ALKALI LOADING IN INFANTS
- Author
-
Mathéová, E, primary, Tischler, V, additional, Pavkovčeková, O, additional, Beňo, P, additional, and Fedorová, E, additional
- Published
- 1980
- Full Text
- View/download PDF
37. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
- Author
-
Bonde Anne-Katrine, Tischler Verena, Kumar Sushil, Soltermann Alex, and Schwendener Reto A
- Subjects
Tumor-associated macrophages (TAMs) ,Macrophage depletion ,Clodronate liposomes ,Tumor progression ,Tumor invasion ,Epithelial-mesenchymal transition (EMT) ,TGF-β ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Several stromal cell subtypes including macrophages contribute to tumor progression by inducing epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis. Tumor associated macrophages (TAM) reside mainly at the invasive front but they also infiltrate tumors and in this process they mainly assume a tumor promoting phenotype. In this study, we asked if TAMs also regulate EMT intratumorally. We found that TAMs through TGF-β signaling and activation of the β-catenin pathway can induce EMT in intratumoral cancer cells. Methods We depleted macrophages in F9-teratocarcinoma bearing mice using clodronate-liposomes and analyzed the tumors for correlations between gene and protein expression of EMT-associated and macrophage markers. The functional relationship between TAMs and EMT was characterized in vitro in the murine F9 and mammary gland NMuMG cells, using a conditioned medium culture approach. The clinical relevance of our findings was evaluated on a tissue microarray cohort representing 491 patients with non-small cell lung cancer (NSCLC). Results Gene expression analysis of F9-teratocarcinomas revealed a positive correlation between TAM-densities and mesenchymal marker expression. Moreover, immunohistochemistry showed that TAMs cluster with EMT phenotype cells in the tumors. In vitro, long term exposure of F9-and NMuMG-cells to macrophage-conditioned medium led to decreased expression of the epithelial adhesion protein E-cadherin, activation of the EMT-mediating β-catenin pathway, increased expression of mesenchymal markers and an invasive phenotype. In a candidate based screen, macrophage-derived TGF-β was identified as the main inducer of this EMT-associated phenotype. Lastly, immunohistochemical analysis of NSCLC patient samples identified a positive correlation between intratumoral macrophage densities, EMT markers, intraepithelial TGF-β levels and tumor grade. Conclusions Data presented here identify a novel role for macrophages in EMT-promoted tumor progression. The observation that TAMs cluster with intra-epithelial fibroblastoid cells suggests that the role of macrophages in tumor-EMT extends beyond the invasive front. As macrophage infiltration and pronounced EMT tumor phenotype correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by inducing EMT locally in tumors.
- Published
- 2012
- Full Text
- View/download PDF
38. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer
- Author
-
Weder Walter, Sos Martin L, Bonde Anne-Katrine, Kristiansen Glen, Schirmer Uwe, Hausladen Silke, Pfeifer Marco, Tischler Verena, Moch Holger, Altevogt Peter, and Soltermann Alex
- Subjects
L1 cell adhesion molecule ,epithelial-mesenchymal transition ,tumor-stroma interface ,prognostic marker ,non-small cell lung cancer ,tissue microarray ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The L1 cell adhesion molecule (L1CAM) is potentially involved in epithelial-mesenchymal transition (EMT). EMT marker expression is of prognostic significance in non-small cell lung cancer (NSCLC). The relevance of L1CAM for NSCLC is unclear. We investigated the protein expression of L1CAM in a cohort of NSCLC patients. L1CAM protein expression was correlated with clinico-pathological parameters including survival and markers of epithelial-mesenchymal transition. Results L1CAM protein expression was found in 25% of squamous cell carcinomas and 24% of adenocarcinomas and correlated with blood vessel invasion and metastasis (p < 0.05). L1CAM was an independent predictor of survival in a multivariate analysis including pT, pN, and pM category, and tumor differentiation grade. L1CAM expression positively correlated with vimentin, beta-catenin, and slug, but inversely with E-cadherin (all p-values < 0.05). E-cadherin expression was higher in the tumor center than in the tumor periphery, whereas L1CAM and vimentin were expressed at the tumor-stroma interface. In L1CAM-negative A549 cells the L1CAM expression was upregulated and matrigel invasion was increased after stimulation with TGF-beta1. In L1CAM-positive SK-LU-1 and SK-LC-LL cells matrigel invasion was decreased after L1CAM siRNA knockdown. Conclusions A subset of NSCLCs with vessel tropism and increased metastasis aberrantly expresses L1CAM. L1CAM is a novel prognostic marker for NSCLCs that is upregulated by EMT induction and appears to be instrumental for enhanced cell invasion.
- Published
- 2011
- Full Text
- View/download PDF
39. Periostin is up-regulated in high grade and high stage prostate cancer
- Author
-
Schraml Peter, Gerhardt Josefine, Mortezavi Ashkan, Hermanns Thomas, Riener Marc-Oliver, Seifert Hans-Helge, Stephan Carsten, Wild Peter J, Fritzsche Florian R, Tischler Verena, Jung Klaus, Moch Holger, Soltermann Alex, and Kristiansen Glen
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far. Methods Here, we evaluated periostin expression in prostate cancer cells and peritumoural stroma immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n = 93) and a test cohort (n = 325). Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed. Results In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%). Increased periostin expression in carcinoma cells was significantly associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort. Whereas periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in tumour stroma was found in most primary and metastatic prostate cancers. High stromal periostin expression was associated with higher Gleason scores (p < 0.001). There was a relationship between stromal periostin expression and shortened PSA relapse free survival times in the training cohort (p < 0.05). Conclusions Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.
- Published
- 2010
- Full Text
- View/download PDF
40. ALKALI LOADING IN INFANTS
- Author
-
Mathéové, A. E., Tischler, V., Pavkovekové, O., Beo, P., and Fedorové, A. E.
- Published
- 1980
41. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer
- Author
-
Marco Pfeifer, Walter Weder, Verena Tischler, Peter Altevogt, Holger Moch, Alex Soltermann, Martin L. Sos, Anne Katrine Bonde, Uwe Schirmer, Glen Kristiansen, Silke Hausladen, University of Zurich, and Tischler, V
- Subjects
Male ,Pathology ,Cancer Research ,Lung Neoplasms ,L1 ,10255 Clinic for Thoracic Surgery ,Cell ,Vimentin ,Kaplan-Meier Estimate ,Metastasis ,Carcinoma, Non-Small-Cell Lung ,tumor-stroma interface ,1306 Cancer Research ,L1 cell adhesion molecule ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,medicine.anatomical_structure ,Oncology ,Gene Knockdown Techniques ,Carcinoma, Squamous Cell ,Adenocarcinoma ,Molecular Medicine ,Female ,RNA Interference ,2730 Oncology ,medicine.medical_specialty ,Epithelial-Mesenchymal Transition ,Neural Cell Adhesion Molecule L1 ,610 Medicine & health ,Biology ,lcsh:RC254-282 ,Cell Line, Tumor ,10049 Institute of Pathology and Molecular Pathology ,Biomarkers, Tumor ,medicine ,Humans ,Neoplasm Invasiveness ,Epithelial–mesenchymal transition ,Lung cancer ,non-small cell lung cancer ,Aged ,A549 cell ,tissue microarray ,Research ,medicine.disease ,1313 Molecular Medicine ,Multivariate Analysis ,Cancer research ,biology.protein ,prognostic marker - Abstract
Background The L1 cell adhesion molecule (L1CAM) is potentially involved in epithelial-mesenchymal transition (EMT). EMT marker expression is of prognostic significance in non-small cell lung cancer (NSCLC). The relevance of L1CAM for NSCLC is unclear. We investigated the protein expression of L1CAM in a cohort of NSCLC patients. L1CAM protein expression was correlated with clinico-pathological parameters including survival and markers of epithelial-mesenchymal transition. Results L1CAM protein expression was found in 25% of squamous cell carcinomas and 24% of adenocarcinomas and correlated with blood vessel invasion and metastasis (p < 0.05). L1CAM was an independent predictor of survival in a multivariate analysis including pT, pN, and pM category, and tumor differentiation grade. L1CAM expression positively correlated with vimentin, beta-catenin, and slug, but inversely with E-cadherin (all p-values < 0.05). E-cadherin expression was higher in the tumor center than in the tumor periphery, whereas L1CAM and vimentin were expressed at the tumor-stroma interface. In L1CAM-negative A549 cells the L1CAM expression was upregulated and matrigel invasion was increased after stimulation with TGF-beta1. In L1CAM-positive SK-LU-1 and SK-LC-LL cells matrigel invasion was decreased after L1CAM siRNA knockdown. Conclusions A subset of NSCLCs with vessel tropism and increased metastasis aberrantly expresses L1CAM. L1CAM is a novel prognostic marker for NSCLCs that is upregulated by EMT induction and appears to be instrumental for enhanced cell invasion.
- Full Text
- View/download PDF
42. Aging and Olfactory Training: A Scoping Review.
- Author
-
Loughnane M, Tischler V, Khalid Saifeldeen R, and Kontaris E
- Abstract
Background and Objectives: Decreased olfactory function commonly occurs alongside the aging process. Research suggests olfactory training (OT) has the potential to improve olfactory and cognitive function in individuals with and without olfactory dysfunction. The degree to which these benefits extend into older age and among those with cognitive impairment (i.e., people with dementia and mild cognitive impairment) is less clear. The purpose of the current review was to investigate the extent to which OT affects olfactory function, cognition, and well-being among older people., Research Design and Methods: A scoping review of the literature was conducted in PubMed, Embase, EbscoHost, and SCOPUS. Articles were considered eligible for original research studies with human populations, included adults aged 55 and older, performed any type of OT, and included a form of olfactory testing. The data from the included studies were synthesized and presented narratively., Results: A total of 23 studies were included. The results suggest that OT provides multiple benefits to older adults, including those with cognitive impairment. Particularly, OT was associated with measurable changes in olfactory function, improved cognitive function, specifically semantic verbal fluency and working memory, reduced depressive symptoms, and protection from cognitive decline., Discussion and Implications: The findings suggest that benefits from OT extend beyond changes in olfactory function and include improved cognitive function, amelioration of depressive symptoms, and protection from cognitive decline. Future research is needed across specific participant groups, including those with differentiated types of dementia, to investigate the olfactory and cognitive benefits of OT., Competing Interests: Author E. Kontaris declares a relationship with Givaudan UK Limited as an employee of the company., (© The Author(s) 2024. Published by Oxford University Press on behalf of The Gerontological Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
43. The glymphatic system in migraine and other headaches.
- Author
-
Vittorini MG, Sahin A, Trojan A, Yusifli S, Alashvili T, Bonifácio GV, Paposhvili K, Tischler V, Lampl C, and Sacco S
- Subjects
- Animals, Blood-Brain Barrier metabolism, Headache metabolism, Brain diagnostic imaging, Brain metabolism, Glymphatic System diagnostic imaging, Glymphatic System metabolism, Migraine Disorders diagnostic imaging, Migraine Disorders metabolism, Nervous System Diseases metabolism
- Abstract
Glymphatic system is an emerging pathway of removing metabolic waste products and toxic solutes from the brain tissue. It is made of a network of perivascular spaces, filled in cerebrospinal and interstitial fluid, encompassing penetrating and pial vessels and communicating with the subarachnoid space. It is separated from vessels by the blood brain barrier and from brain tissue by the endfeet of the astrocytes rich in aquaporin 4, a membrane protein which controls the water flow along the perivascular space. Animal models and magnetic resonance (MR) studies allowed to characterize the glymphatic system function and determine how its impairment could lead to numerous neurological disorders (e.g. Alzheimer's disease, stroke, sleep disturbances, migraine, idiopathic normal pressure hydrocephalus). This review aims to summarize the role of the glymphatic system in the pathophysiology of migraine in order to provide new ways of approaching to this disease and to its therapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. Mass Spectrometry-Based Profiling of Histone Post-Translational Modifications in Uveal Melanoma Tissues, Human Melanocytes, and Uveal Melanoma Cell Lines - A Pilot Study.
- Author
-
Herwig-Carl MC, Sharma A, Tischler V, Pelusi N, Loeffler KU, Holz FG, Zeschnigk M, Landreville S, Auw-Haedrich C, Noberini R, and Bonaldi T
- Subjects
- Humans, Histones, Pilot Projects, Melanocytes metabolism, Cell Line, Mass Spectrometry, Melanoma metabolism, Uveal Neoplasms pathology
- Abstract
Purpose: Epigenetic alterations in uveal melanoma (UM) are still neither well characterized, nor understood. In this pilot study, we sought to provide a deeper insight into the possible role of epigenetic alterations in the pathogenesis of UM and their potential prognostic relevance. To this aim, we comprehensively profiled histone post-translational modifications (PTMs), which represent epigenetic features regulating chromatin accessibility and gene transcription, in UM formalin-fixed paraffin-embedded (FFPE) tissues, control tissues, UM cell lines, and healthy melanocytes., Methods: FFPE tissues of UM (n = 24), normal choroid (n = 4), human UM cell lines (n = 7), skin melanocytes (n = 6), and uveal melanocytes (n = 2) were analyzed through a quantitative liquid chromatography-mass spectrometry (LC-MS) approach., Results: Hierarchical clustering showed a clear separation with several histone PTMs that changed significantly in a tumor compared to normal samples, in both tissues and cell lines. In addition, several acetylations and H4K20me1 showed lower levels in BAP1 mutant tumors. Some of these changes were also observed when we compared GNA11 mutant tumors with GNAQ tumors. The epigenetic profiling of cell lines revealed that the UM cell lines MP65 and UPMM1 have a histone PTM pattern closer to the primary tissues than the other cell lines analyzed., Conclusions: Our results suggest the existence of different histone PTM patterns that may be important for diagnosis and prognosis in UM. However, further analyses are needed to confirm these findings in a larger cohort. The epigenetic characterization of a panel of UM cell lines suggested which cellular models are more suitable for epigenetic investigations.
- Published
- 2024
- Full Text
- View/download PDF
45. Migraine - a borderland disease to epilepsy: near it but not of it.
- Author
-
Paungarttner J, Quartana M, Patti L, Sklenárová B, Farham F, Jiménez IH, Soylu MG, Vlad IM, Tasdelen S, Mateu T, Marsico O, Reina F, Tischler V, and Lampl C
- Subjects
- Humans, Anticonvulsants therapeutic use, Comorbidity, Migraine Disorders diagnosis, Migraine Disorders genetics, Migraine Disorders epidemiology, Epilepsy etiology, Epilepsy genetics, Migraine with Aura genetics
- Abstract
Background: Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disorders has been of interest for decades and innovations concerning diagnosing and treatment enable new insights into their relationship., Findings: Although appearing to be distinct at first glance, both diseases exhibit a noteworthy comorbidity, shared pathophysiological pathways, and significant overlaps in characteristics like clinical manifestation or prophylactic treatment. This review aims to explore the intricate relationship between these two conditions, shedding light on shared pathophysiological foundations, genetic interdependencies, common and distinct clinical features, clinically overlapping syndromes, and therapeutic similarities. There are several shared pathophysiological mechanisms, like CSD, the likely underlying cause of migraine aura, or neurotransmitters, mainly Glutamate and GABA, which represent important roles in triggering migraine attacks and seizures. The genetic interrelations between the two disorders can be observed by taking a closer look at the group of familial hemiplegic migraines, which are caused by mutations in genes like CACNA1A, ATP1A2, or SCN1A. The intricate relationship is further underlined by the high number of shared clinical features, which can be observed over the entire course of migraine attacks and epileptic seizures. While the variety of the clinical manifestation of an epileptic seizure is naturally higher than that of a migraine attack, a distinction can indeed be difficult in some cases, e.g. in occipital lobe epilepsy. Moreover, triggering factors like sleep deprivation or alcohol consumption play an important role in both diseases. In the period after the seizure or migraine attack, symptoms like speech difficulties, tiredness, and yawning occur. While the actual attack of the disease usually lasts for a limited time, research indicates that individuals suffering from migraine and/or epilepsy are highly affected in their daily life, especially regarding cognitive and social aspects, a burden that is even worsened using antiseizure medication. This medication allows us to reveal further connections, as certain antiepileptics are proven to have beneficial effects on the frequency and severity of migraine and have been used as a preventive drug for both diseases over many years., Conclusion: Migraine and epilepsy show a high number of similarities in their mechanisms and clinical presentation. A deeper understanding of the intricate relationship will positively advance patient-oriented research and clinical work., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
46. Value of Diagnostic Tools in the Diagnosis of Osteomyelitis: Pilot Study to Establish an Osteomyelitis Score.
- Author
-
Hackenberg RK, Schmitt-Sánchez F, Endler C, Tischler V, Surendar J, Welle K, Kabir K, and Schildberg FA
- Abstract
Osteomyelitis (OM) remains one of the most feared complications in bone surgery and trauma. Its diagnosis remains a major challenge due to lack of guidelines. The aim of this study was to prospectively analyze the value of the most common and available diagnostic tools and to establish an OM score to derive treatment recommendations. All patients with suspected OM were included in a prospective pilot study. All patients underwent blood sampling for C-reactive protein and white blood cell count analysis. Magnetic resonance imaging (MRI), and microbiologic and histopathologic samples, were taken from representative sites of initial debridement. All patients were treated according to their OM test results and followed for at least one year. Subsequently, the value of individual or combined diagnostic tools was analyzed in patients with confirmed OM and in patients in whom OM was ruled out. Based on these findings, an OM score was developed that included MRI, microbiology, and histopathology. The score identified all control patients and all but one OM patient, resulting in a correct diagnosis of 93.3%, which was validated in a second independent larger cohort. This was the first study to analyze the value of the most commonly used tools to diagnose OM. The proposed OM score provides a simple scoring system to safely interpret test results with high accuracy.
- Published
- 2023
- Full Text
- View/download PDF
47. Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.
- Author
-
Depoilly T, Garinet S, van Kempen LC, Schuuring E, Clavé S, Bellosillo B, Ercolani C, Buglioni S, Siemanowski J, Merkelbach-Bruse S, Tischler V, Demes MC, Paridaens H, Sibille C, de Montpreville VT, Rouleau E, Bartczak A, Pasieka-Lis M, Teo RYW, Chuah KL, Barbosa M, Quintana C, Biscuola M, Delgado-Garcia M, Vacirca D, Rappa A, Cashmore M, Smith M, Jasionowicz P, Meeney A, Desmeules P, Terris B, and Mansuet-Lupo A
- Subjects
- Humans, In Situ Hybridization, Fluorescence, Mutation, Protein-Tyrosine Kinases genetics, Protein-Tyrosine Kinases metabolism, Proto-Oncogene Proteins genetics, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms diagnosis, Lung Neoplasms genetics
- Abstract
Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, including fusion genes. This retrospective study evaluated the Idylla GeneFusion prototype, an automated and ease-of-use (<2 minutes) test, with a short turnaround time (3 hours) to detect fusions involving ALK, ROS1, RET, and NTRK1/2/3 genes and MET exon 14 skipping. This multicenter study (18 centers) included 313 tissue samples from lung cancer patients with 97 ALK, 44 ROS1, 20 RET, and 5 NTRKs fusions, 32 MET exon 14 skipping, and 115 wild-type samples, previously identified with reference methods (RNA-based next-generation sequencing/fluorescence in situ hybridization/quantitative PCR). Valid results were obtained for 306 cases (98%), overall concordance between Idylla and the reference methods was 89% (273/306); overall sensitivity and specificity were 85% (165/193) and 96% (108/113), respectively. Discordances were observed in 28 samples, where Idylla did not detect the alteration identified by the reference methods; and 5 samples where Idylla identified an alteration not detected by the reference methods. All of the ALK-, ROS1-, and RET-specific fusions and MET exon 14 skipping identified by Idylla GeneFusion were confirmed by reference method. To conclude, Idylla GeneFusion is a clinically valuable test that does not require a specific infrastructure, allowing a rapid result. The absence of alteration or the detection of expression imbalance only requires additional testing by orthogonal methods., (Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. Object Handling for People With Dementia: A Scoping Review and the Development of Intervention Guidance.
- Author
-
D'Andrea F, Dening T, and Tischler V
- Abstract
Background and Objectives: Among the various psychosocial interventions aiming at improving behavior, quality of life, and the well-being of people with dementia, one that has attracted recent attention has been object handling. This scoping review synthesizes available studies on object handling for people with dementia, their effects, and methodological characteristics and describes its components and likely domains., Research Design and Methods: The search was conducted using CINAHL, PsycINFO, MEDLINE, PsycARTICLES, Academic Search Elite, and Art Full Text, plus review of reference lists and hand search. Data from the studies included were chattered and reported in narrative form., Results: Eleven studies were included; of which, 9 described a group intervention and 10 investigated the distinctive value of heritage items. Studies used a mixed-methods or qualitative design and varied in their procedures, including number of sessions and length of intervention. Most studies reported positive effects on well-being, mood, and emotion in those with dementia. Qualitative investigations revealed that the co-construction of an object's meaning facilitated new learning, social inclusion, and change in attitudes toward dementia. From the review and stakeholder consultations, a definition of object handling is proposed, which includes three components: presenting, receiving, and responding., Discussion and Implications: The findings suggest that people with dementia may benefit from object handling interventions as a means of improving well-being, mood, and social inclusion. The review highlighted a variety of approaches used and a small number of studies were identified under the term of "object handling." Further studies are needed to examine the complexity of object handling, its impact within dementia care settings, and that explicitly use the term "object handling." Given the focus to date on heritage, archive, and museum objects, more studies involving the handling of everyday material objects are needed because these are by definition highly accessible., (© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
49. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
- Author
-
Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Kerr KM, Peters S, and Stahel RA
- Subjects
- Humans, Mutation, Neoplasm Recurrence, Local, Piperazines, Prognosis, Pyridines, Pyrimidines, Lung Neoplasms genetics, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Introduction: KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849)., Methods: KRAS mutations were evaluated in formalin-fixed, paraffin-embedded tissue sections by a microfluidic-based multiplex polymerase chain reaction platform as a component of the previously published European Thoracic Oncology Platform Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I to III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathologic characteristics, molecular profiles, and postoperative patient outcome (overall survival, relapse-free survival, time-to-relapse) were explored., Results: KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 [49%]) with I or II or III stage respective distribution of 53% or 24% or 22% and median follow-up of 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0% (95% confidence interval (CI): 35.0% to 41.0%), with Kr_G12C mutation representing 17.0% (95% CI: 14.7% to 19.4%). In the "histologic-subtype" cohort, Kr_G12C prevalence was 10.5% (95% CI: 9.2% to 11.9%). When adjusting for clinicopathologic characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or nonexistence of KRAS mutation was identified in the adenocarcinoma cohort alone and in the "histologic-subtype" cohort. For overall survival in adenocarcinomas, hazard ratio (HR)
G12C versus other KRAS is equal to 1.39 (95% CI: 1.03 to 1.89, p = 0.031) and HRG12C versus no KRAS is equal to 1.32 (95% CI: 1.03 to 1.69, p = 0.028) (both also significant in the "histologic-subtype" cohort). For time-to-relapse, HRG12C versus other KRAS is equal to 1.41 (95% CI: 1.03 to 1.92, p = 0.030). In addition, among all patients, for relapse-free survival, HRG12C versus no KRAS is equal to 1.27 (95% CI: 1.04 to 1.54, p = 0.017)., Conclusions: In this large, clinically annotated stage I to III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathologic characteristics) among adenocarcinomas and in unselected NSCLCs., (Copyright © 2021 International Association for the Study of Lung Cancer. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
50. A requirement for p120-catenin in the metastasis of invasive ductal breast cancer.
- Author
-
Kurley SJ, Tischler V, Bierie B, Novitskiy SV, Noske A, Varga Z, Zürrer-Härdi U, Brandt S, Carnahan RH, Cook RS, Muller WJ, Richmond A, and Reynolds AB
- Subjects
- Animals, Cadherins genetics, Catenins genetics, Cell Adhesion, Female, Humans, Mice, Tumor Microenvironment, Delta Catenin, Breast Neoplasms genetics
- Abstract
We report here the effects of targeted p120-catenin (encoded by CTNND1 ; hereafter denoted p120) knockout (KO) in a PyMT mouse model of invasive ductal (mammary) cancer (IDC). Mosaic p120 ablation had little effect on primary tumor growth but caused significant pro-metastatic alterations in the tumor microenvironment, ultimately leading to a marked increase in the number and size of pulmonary metastases. Surprisingly, although early effects of p120-ablation included decreased cell-cell adhesion and increased invasiveness, cells lacking p120 were almost entirely unable to colonized distant metastatic sites in vivo The relevance of this observation to human IDC was established by analysis of a large clinical dataset of 1126 IDCs. As reported by others, p120 downregulation in primary IDC predicted worse overall survival. However, as in the mice, distant metastases were almost invariably p120 positive, even in matched cases where the primary tumors were p120 negative. Collectively, our results demonstrate a strong positive role for p120 (and presumably E-cadherin) during metastatic colonization of distant sites. On the other hand, downregulation of p120 in the primary tumor enhanced metastatic dissemination indirectly via pro-metastatic conditioning of the tumor microenvironment., Competing Interests: Competing interestsThe authors declare no competing or financial interests., (© 2021. Published by The Company of Biologists Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.